Essais liés10clinical trials
VilleSendailocalisation
PaysJapanlocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT07175285

Ouvrir le site du centre

Essais cliniques associés

10
MoléculeIndication / populationPhaseNCTTitreStatut
Tacabrutideg Cancer Phase 3 NCT06846671 CaDAnCe-302 — A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors RECRUITING
Zanidatamab Cancer Phase 3 NCT06282575 Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer RECRUITING
MT-1186 Sclérose latérale amyotrophique Phase 3 NCT05151471 Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS TERMINATED
BENCHMARK-SLE — A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants Lupus À vérifier NCT07175285 BENCHMARK-SLE — A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants RECRUITING
MT-1186 Sclérose latérale amyotrophique Phase 3 NCT04165824 Safety Study of Oral Edaravone Administered in Subjects With ALS COMPLETED
MT-1186 Sclérose latérale amyotrophique Phase 3 NCT04577404 Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS) COMPLETED
BIIB059 (litifilimab) Lupus Phase 3 NCT06044337 AMETHYST LTE — A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus ENROLLING_BY_INVITATION
Litifilimab Lupus Phase 2/3 NCT05531565 AMETHYST — A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus ACTIVE_NOT_RECRUITING
MT-1186 Sclérose latérale amyotrophique Phase 3 NCT04569084 Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS TERMINATED
Pembrolizumab Parkinson Phase 3 NCT03358472 Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) COMPLETED